Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens.

ABSTRACT:

Introduction

Critically ill COVID-19 patients are at increased risk of thrombosis with an enhanced risk of bleeding. We aimed to explore the role of anti-factor Xa levels in optimizing the high-intensity anticoagulation's safety and efficacy and finding possible associations between D-dimer levels, cytokine storm markers, and COVID-19-induced coagulopathy or thrombophilia.

Methods

Retrospective cohort study conducted on 69 critically ill COVID-19 patients who received three regimens of higher intensity anticoagulation.

Results

Seventeen patients (24.6%) received high-dose enoxaparin prophylaxis, 29 patients (42%) received therapeutic doses of enoxaparin, and 23 patients (33.3%) were on therapeutic unfractionated heparin infusion. Fewer than one-third of the whole coho

SUBMITTER: Hamad MA 

PROVIDER: S-EPMC8516376 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature